Arc Capital's Singapore New Office

Arc Capital’s Singapore New Office

This year has proven to be of great growth for ARC Capital! After the additions of Wuhan, Mexico City and Sao Paolo ARC Capital is pleased to announce that it has also expanded into Singapore! Singapore is our 7th Global Office, in a growing network allowing us to bring more reach and more growth opportunities for our clients.

In the heart of South East Asia and the ASEAN community, Singapore is the hub for business in the fastest growing region in the world. Our experienced managing director, Christian-Laurent Bonte adds years of M&A and financing transactions across Asia.

From Singapore, ARC Capital will be able to assist its clients in its dealings with Thailand, Indonesia and the entire region. With a population of over 500M and a sizeable GDP, experts say the region will be the locomotive of future growth in the world.

This move also strengthens our presence and focus in the Emerging Markets, especially those in APAC and Latin America. Stay tuned for more updates from ARC Capital as we continue our growth story, a testimony to an also growing number of satisfied clients.

Continue reading

ARC Group Announces US$15 Million Investment Commitment in Cloudbreak Pharma Inc. (HKEX: 2592)

ARC Group Announces US$15 Million Investment Commitment in Cloudbreak Pharma Inc. (HKEX: 2592)

HONG KONG, 18 June 2026 — ARC Group today announced that it has committed to invest in Cloudbreak Pharma Inc. (HKEX: 2592), a clinical-stage ophthalmology biotechnology company with operations across the United States and China, following the signing of a share subscription agreement through its wholly owned subsidiary ARC Group International Limited. The transaction marks […]
Rising Together | ARC Dragon Boat Team Takes to the Water
Bio Green Med Solution, Inc. Announces Business Combination Agreement to Acquire Future NRG Sdn. Bhd.
Inside ARC Group | University of Nottingham Ningbo China

Please complete this form to download the case study

This field is for validation purposes and should be left unchanged.
*Required before submission